TickerTain
$SPCX····$NVDA····$MSFT····$GOOGL····$ANTHROPIC·$TSLA····$CRWV····$NBIS····$HIMS····$TSM····$ASML····$FIGURE·$LYFT····$UBER····$SNOW····$META····$ELEVENLABS·$CURSOR·$COGNITION·$OPENAI·$AAPL····$RKLB····$XAI·$AMZN····$AMD····$000660.KS····$INTC····
← newsroom
Longevity & Aging · Longevity-native brands winning via lifestyle identity and biomarker-driven optimization
now playing · Longevity & Aging
AI in Healthcaretailwindscore 9/10max marchione
AI doctors emerging via ensemble models, proprietary clinical canon, and memory architecture
Superpower builds AI clinical reasoning using ensemble of open/closed models, separate memory architecture (superior to ChatGPT's), and proprietary 'clinical canon' database from frontier d…
GLP-1 & Metabolic Drugstailwindscore 9/10max marchione
Peptides to become mega consumer category with GLP-1s leading, compounding facing patent cliff
GLP-1 adoption accelerating faster than predicted (1 in 3 Americans may try by year-end). Peptides expanding beyond weight loss to cognition, energy, sleep, healing. Current compounding win…
Longevity & Agingtailwindscore 8/10max marchione
Longevity-native brands winning via lifestyle identity and biomarker-driven optimization
Superpower's longevity-native branding (viral hoodies, biological age leaderboards for B2B) creates proud lifestyle identity vs Hims' 'hide the box' stigma. Word-of-mouth growth driven by m…
AI Economics & Business Modelsmixedscore 8/10max marchione
ChatGPT as health demand aggregator forces companies to become perfect supply aggregators
If ChatGPT becomes universal health front door (5-10% queries already health, wants context, moves to action layer), winning strategy shifts to being lowest-cost, vertically integrated supp…
Healthcare Systems & Policytailwindscore 8/10max marchione
Pharma 2.0 shift: wellness drugs direct-to-consumer bypassing payers and health systems
Structural shift from Pharma 1.0 (disease drugs, payer-funded, health system distribution) to Pharma 2.0 (wellness drugs, consumer-funded, DTC distribution). Eli Lilly/Novo poorly positione…
Gene & Cell Therapytailwindscore 7/10max marchione
Gene editing identified as next major category after peptides, 10-year horizon
After peptides run their course (many years), gene-based therapies could surpass signaling-based therapies in effectiveness. Barriers: higher risk, ethical questions, science not yet mature…